The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 21, 2017

Filed:

Sep. 15, 2014
Applicants:

Steven J. Burden, Sharon, CT (US);

Wei Zhang, New York, NY (US);

Maartje Huijbers, Leiden, NL;

Johannes J. Verschuuren, Oegstgeest, NL;

Silvère M. Van Der Maarel, Oegstgeest, NL;

Inventors:

Steven J. Burden, Sharon, CT (US);

Wei Zhang, New York, NY (US);

Maartje Huijbers, Leiden, NL;

Johannes J. Verschuuren, Oegstgeest, NL;

Silvère M. van der Maarel, Oegstgeest, NL;

Assignees:

New York University, New York, NY (US);

Leiden University Medical Center, Leiden, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61P 21/04 (2006.01); C07K 14/705 (2006.01); C07K 16/42 (2006.01); A61K 35/16 (2015.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
C07K 16/4258 (2013.01); A61K 35/16 (2013.01); A61K 38/1774 (2013.01); C07K 14/4713 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01);
Abstract

Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.


Find Patent Forward Citations

Loading…